IL270018A - - Google Patents

Info

Publication number
IL270018A
IL270018A IL27001819A IL27001819A IL270018A IL 270018 A IL270018 A IL 270018A IL 27001819 A IL27001819 A IL 27001819A IL 27001819 A IL27001819 A IL 27001819A IL 270018 A IL270018 A IL 270018A
Authority
IL
Israel
Application number
IL27001819A
Other languages
English (en)
Other versions
IL270018B (en
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=63857137&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL270018(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Publication of IL270018A publication Critical patent/IL270018A/en
Publication of IL270018B publication Critical patent/IL270018B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C303/00—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides
    • C07C303/02—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides of sulfonic acids or halides thereof
    • C07C303/22—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides of sulfonic acids or halides thereof from sulfonic acids, by reactions not involving the formation of sulfo or halosulfonyl groups; from sulfonic halides by reactions not involving the formation of halosulfonyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/02—Sulfonic acids having sulfo groups bound to acyclic carbon atoms
    • C07C309/03—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C309/04—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing only one sulfo group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
IL270018A 2017-04-21 2018-04-18 A salt of a derivative compound of aminopyridine, its crystalline form and a process for its preparation IL270018B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20170051687 2017-04-21
PCT/KR2018/004473 WO2018194356A1 (en) 2017-04-21 2018-04-18 Salt of an aminopyridine derivative compound, a crystalline form thereof, and a process for preparing the same

Publications (2)

Publication Number Publication Date
IL270018A true IL270018A (enExample) 2019-12-31
IL270018B IL270018B (en) 2022-08-01

Family

ID=63857137

Family Applications (2)

Application Number Title Priority Date Filing Date
IL294666A IL294666B2 (en) 2017-04-21 2018-04-18 A salt of a derivative compound of aminopyridine, its crystalline form and a process for its preparation
IL270018A IL270018B (en) 2017-04-21 2018-04-18 A salt of a derivative compound of aminopyridine, its crystalline form and a process for its preparation

Family Applications Before (1)

Application Number Title Priority Date Filing Date
IL294666A IL294666B2 (en) 2017-04-21 2018-04-18 A salt of a derivative compound of aminopyridine, its crystalline form and a process for its preparation

Country Status (22)

Country Link
US (3) US11453656B2 (enExample)
EP (1) EP3612529A4 (enExample)
JP (2) JP7126514B2 (enExample)
KR (3) KR102629654B1 (enExample)
CN (1) CN110869367B (enExample)
AR (1) AR111469A1 (enExample)
AU (2) AU2018256227B2 (enExample)
CA (1) CA3059543A1 (enExample)
CO (1) CO2019011578A2 (enExample)
EA (1) EA201992501A1 (enExample)
IL (2) IL294666B2 (enExample)
MA (1) MA49696A (enExample)
MX (2) MX392634B (enExample)
MY (1) MY201919A (enExample)
NZ (1) NZ758443A (enExample)
PH (1) PH12019502370A1 (enExample)
SA (1) SA519410342B1 (enExample)
SG (1) SG11201909615YA (enExample)
TW (1) TWI776882B (enExample)
UA (1) UA124364C2 (enExample)
WO (1) WO2018194356A1 (enExample)
ZA (1) ZA201907687B (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR111469A1 (es) * 2017-04-21 2019-07-17 Yuhan Corp Sal de un compuesto del derivado de aminopiridina, una forma cristalina de la misma, y un proceso para preparar la misma
ES2962961T3 (es) 2017-07-28 2024-03-22 Yuhan Corp Procedimiento de preparación de n-(5-((4-(4-(dimetilamino)metil)-3-fenil-1h-pirazol-1-il)pirimidin-2-il)amino)-4-metoxi-2-morfolinofenil)acrilamida haciendo reaccionar la amina correspondiente con un cloruro de 3-halo-propionilo
KR20200043618A (ko) * 2018-10-18 2020-04-28 주식회사유한양행 아미노피리미딘 유도체 또는 이의 염을 포함하는 경구투여용 약학 조성물
KR101973074B1 (ko) * 2018-11-30 2019-04-26 주식회사 티움바이오 퓨로피리미딘 화합물의 염 및 결정형, 및 이를 포함하는 약학적 조성물
CN111349084B (zh) * 2018-12-21 2022-11-25 深圳市塔吉瑞生物医药有限公司 用于抑制蛋白激酶活性的氨基嘧啶类化合物
MX2021010265A (es) 2019-02-26 2021-09-23 Janssen Biotech Inc Terapias de combinacion y estratificacion de pacientes con anticuerpos anti-egfr/c-met biespecificos.
MY208668A (en) 2019-05-14 2025-05-23 Janssen Biotech Inc Combination therapies with bispecific anti-egfr/c-met antibodies and 3rd generation egfr tyrosine kinase inhibitors
BR112021022828A2 (pt) * 2019-05-14 2022-04-12 Janssen Biotech Inc Terapias combinadas com anticorpos biespecíficos anti-egfr/c-met e inibidores de egfr tirosina-quinase de terceira geração
US11850248B2 (en) 2019-05-14 2023-12-26 Yuhan Corporation Therapies with 3rd generation EGFR tyrosine kinase inhibitors
BR112022015140A2 (pt) 2020-02-12 2022-10-11 Janssen Biotech Inc Tratamento de pacientes que têm mutações de salto do éxon 14 de c-met
TWI923583B (zh) * 2020-04-14 2026-05-01 美商健生生物科技公司 包含胺基嘧啶衍生物或其醫藥上可接受之鹽之用於經口投予之醫藥組成物
EP4349835A4 (en) * 2021-06-01 2025-06-25 Hangzhou Solipharma Co., Ltd. Hydrated crystal form of lazertinib methanesulfonate, process for its preparation and use thereof
CA3228195A1 (en) 2023-05-23 2025-06-30 Janssen Biotech, Inc. Methods for treatment of non-small cell lung cancer (nsclc)
IL326946A (en) 2023-09-05 2026-05-01 Janssen Biotech Inc Methods of treating non-small cell lung cancer
WO2026042017A1 (en) 2024-08-19 2026-02-26 Janssen Biotech, Inc. Amivantamab in combination with lazertinib for the treatment of non-small cell lung cancer (nsclc)

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE025742T2 (hu) 2003-12-25 2016-04-28 Eisai R&D Man Co Ltd 4-(3-klór-4-(ciklopropilamino-karbonil)aminofenoxi)-7-metoxi-6-kinolin-karboxamid vagy szolvátja sójának kristálya és eljárás elõállításukra
PL1720853T3 (pl) 2004-02-11 2016-06-30 Natco Pharma Ltd Nowa odmiana polimorficzna metanosulfonianu imatynibu i sposób jej otrzymywania
AU2009262068C1 (en) 2008-06-27 2015-07-02 Celgene Car Llc Heteroaryl compounds and uses thereof
CZ2009570A3 (cs) 2009-08-26 2011-03-09 Zentiva, K. S. Príprava, stabilizace a využití polymorfu imatinib mesylátu pro vývoj lékových forem
CA2780892C (en) * 2009-11-13 2017-02-14 Genosco Kinase inhibitors
WO2012077136A2 (en) * 2010-12-06 2012-06-14 Msn Laboratories Limited Process for the preparation of benzimidazole derivatives and its salts
DK3686193T3 (da) * 2011-07-27 2022-05-30 Astrazeneca Ab 2-(2,4,5-substitueret anilino)pyrimidinforbindelser
CN104540822B (zh) 2013-07-08 2016-08-31 杭州普晒医药科技有限公司 达拉菲尼甲磺酸盐的晶型及其制备方法
US20170166598A1 (en) 2014-05-13 2017-06-15 Ariad Pharmaceuticals, Inc. Heteroaryl compounds for kinase inhibition
EP3929190B1 (en) * 2014-10-13 2024-12-25 Yuhan Corporation Compounds and compositions for modulating egfr mutant kinase activities
CN104788427B (zh) 2015-02-05 2017-05-31 上海泓博智源医药股份有限公司 3‑(2‑嘧啶氨基)苯基丙烯酰胺类化合物及其应用
KR101794186B1 (ko) 2015-10-30 2017-11-08 한국기술교육대학교 산학협력단 전기자동차용 급전장치
AR111469A1 (es) 2017-04-21 2019-07-17 Yuhan Corp Sal de un compuesto del derivado de aminopiridina, una forma cristalina de la misma, y un proceso para preparar la misma
KR20200043618A (ko) 2018-10-18 2020-04-28 주식회사유한양행 아미노피리미딘 유도체 또는 이의 염을 포함하는 경구투여용 약학 조성물

Also Published As

Publication number Publication date
US20230021395A1 (en) 2023-01-26
KR20230175161A (ko) 2023-12-29
KR20180118535A (ko) 2018-10-31
US12428401B2 (en) 2025-09-30
TW201841910A (zh) 2018-12-01
SA519410342B1 (ar) 2023-02-09
US20240279203A1 (en) 2024-08-22
AU2022203486A1 (en) 2022-06-09
US20210139461A1 (en) 2021-05-13
MX392634B (es) 2025-03-24
TWI776882B (zh) 2022-09-11
IL294666B1 (en) 2024-01-01
CN110869367B (zh) 2023-09-15
MX2022006357A (es) 2022-06-23
AU2018256227A1 (en) 2019-10-31
CN110869367A (zh) 2020-03-06
AU2022203486B2 (en) 2024-06-06
PH12019502370A1 (en) 2020-07-13
MA49696A (fr) 2020-06-03
US11453656B2 (en) 2022-09-27
US11981659B2 (en) 2024-05-14
JP2022166179A (ja) 2022-11-01
MY201919A (en) 2024-03-23
NZ758443A (en) 2023-03-31
CO2019011578A2 (es) 2020-02-28
IL270018B (en) 2022-08-01
SG11201909615YA (en) 2019-11-28
UA124364C2 (uk) 2021-09-01
CA3059543A1 (en) 2018-10-25
EP3612529A4 (en) 2020-11-18
EA201992501A1 (ru) 2020-02-18
JP2020517611A (ja) 2020-06-18
JP7390444B2 (ja) 2023-12-01
IL294666A (en) 2022-09-01
KR102629654B1 (ko) 2024-01-29
KR102835717B1 (ko) 2025-07-18
IL294666B2 (en) 2024-05-01
ZA201907687B (en) 2023-04-26
AU2018256227B2 (en) 2022-03-03
EP3612529A1 (en) 2020-02-26
JP7126514B2 (ja) 2022-08-26
BR112019021868A2 (pt) 2020-05-26
KR20250111074A (ko) 2025-07-22
AR111469A1 (es) 2019-07-17
WO2018194356A1 (en) 2018-10-25

Similar Documents

Publication Publication Date Title
BR122021000189A2 (enExample)
BR112019008823A2 (enExample)
BR112019025875B1 (pt) Sistema de cilindro com estrutura de ocupação de movimento relativo
BR112020011860B1 (pt) Dispositivo cirúrgico para cortar uma lente dentro de um saco capsular de um olho
BR112020006283B1 (pt) Placa refinadora, e, refinador para tratamento mecânico de material orgânico/celulósico
BR112020009729B1 (pt) Inibidores de acss2 e métodos de uso dos mesmos
BR112020008714B1 (pt) Uso de medicamentos serotoninérgicos para tratar trombocitopenia induzida por vírus
BR112020006992B1 (pt) Dispositivo de recolhimento e método para o recolhimento de uma embarcação
BR112019023976B1 (pt) Sistema e método para comunicar dados de saúde em um ambiente de cuidados de saúde
BR112020003314B1 (pt) Sistema terapêutico transdérmico para administração transdérmica de um agente ativo, seu método de fabricação, usos de emulsificante, e método para estabilizar uma mistura de revestimento bifásica
BR112020003112B1 (pt) Método de garantir a viabilidade de uma máquina para uma tarefa agendada
BR112020002577B1 (pt) Método de melhoria de rendimento de centrifugação dupla para purificação de óleo nutritivo
BR112019016885B1 (pt) Remodelagem de imagem integrada e codificação de vídeo
BR112019027876B1 (pt) Método de codificação para uma comunicação sem fio, codificador, método de decodificação, decodificador, aparelho de comunicação, meio de armazenagem legível por computador, e sistema de comunicações
BR112020001354B1 (pt) Método, em uma primeira estação base, para suportar posicionamento de um dispositivo móvel e primeira estação base para suportar posicionamento de um dispositivo móvel
BR112019026818B1 (pt) Método de codificação, método de decodificação, aparelho, aparelho de comunicações, terminal, estação base e mídia legível por computador
BR102018011961B1 (pt) Sistemas, métodos e meio não transitório legível por computador para analisar cores a partir de uma plataforma de mídia social
BR112019026880B1 (pt) Método de comunicação, método para receber dados, e, dispositivo
BR112019023944B1 (pt) Combinação farmacêutica para o tratamento de um câncer
BR112019021396B1 (pt) Processo para fabricação de pululano
BR102018003507B1 (pt) Sistema de isolamento de tensão de tambor de guincho
BR112019016182B1 (pt) Método para diagnosticar risco de revisão relacionado a implante
BR112019014127B1 (pt) Composição farmacêutica para tratamento de tumores
BR112019017156B1 (pt) Dispositivo, sistema e método de gerenciamento de recepção de pedido, e, meio de armazenamento legível por computador
BR102017026429B1 (pt) Método de extração subsequente de ácidos graxos e dna genômico a partir de dípteros